FL Judge Cites FDA Role As He Dismisses Novo Compounding Lawsuit

A federal district court said it is FDA’s role, not the states, to regulate compounding as it dismissed a lawsuit filed by Novo Nordisk against compounders of its semaglutide GLP-1 drugs, boosting compounders’ stance that only FDA has the authority to enforce federal drug law. The court said the company didn’t have grounds for the claim compounders violated the state’s unfair trade practices law. It’s the latest defeat for Novo, which along with its fellow GLP-1 manufacturer Eli Lilly has...